Skip to main content

Remote Job Finders (RJF)

Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more

Moderna appears to have aligned with the FDA ahead of an advisory committee meeting for its mRNA-based flu vaccine, which the regulator initially turned away in February; biotech IPOs are going gangbusters, including two new records raises in as many weeks; layoffs continue across biopharma; plus much more.

PwC declares biopharma ecosystem ‘back to full health’ as M&A buoys sector

Precision science is ruling the M&A scene as pharmas prepare for loss of exclusivity on key products, PwC says in a new report. Biotechs should be prepared with a dual-track process with the IPO window now open.

Putting the wrong foot forward: 5 tricky interview questions

Even something as simple as “Tell me about yourself” can trip up biopharma professionals during job interviews. Two recruiting experts discuss what candidates should and shouldn’t say when answering five specific questions.

Germany rethinking drug price reforms after Lilly, Boehringer withdraw investments: Reuters

Weeks after Boehringer Ingelheim and Eli Lilly retracted billions of dollar in German commitments, the nation’s government is reportedly changing a contentious element of its planned healthcare reforms.

Consummate chameleon Amylyx nears regulatory run in obesity surgery complication

After suffering the market withdrawal of its only product, Amylyx is gearing up for a pivotal Phase 3 readout in post-bariatric hypoglycemia. But the company’s driving ethos is still to treat “debilitating, devastating” neurodegenerative diseases, co-CEO Justin Klee told BioSpace.
Scroll to top